Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck

Zeng B. Zhu, James Michael Mathis, Sharmila K. Makhija, Baogen Lu, Minghui Wang, Shaonin Ji, Angel A. Rivera, Eben L. Rosenthal, Gene P. Siegal, David T. Curiel

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Conventional cancer treatments are not adequate for the majority of most patients stricken with squamous cell carcinomas of the head and neck (SCCHN). Conditionally replicating adenoviruses (CRAds) represent a promising new modality for treating of neoplastic diseases, including SCCHN. Specifically, CRAd agents infect tumor cells and selectively replicate within them, thus causing their death while sparing surrounding normal cells in the host. Oncolysis results from the replicative life cycle of the virus, which lyses infected tumor cells and releases viral progeny for propagation of infection and resultant lysis of neighboring cancer cells, sparing normal host cells. However, to date there have been two main limitations to successful clinical application of these CRAd agents: poor infectivity and poor tumor specificity. Here we report the construction of a CRAd agent, CRAd-CXCR4.F5/3, in which the adenovirus E1 gene is driven by a tumor-specific CXCR4 promoter, and the viral infectivity is enhanced by a fiber modification, F5/3, containing an Ad3 knob chimeric fiber protein. As expected, this agent improved both of the viral infectivity and tumor specificity as evaluated in established SCCHN tumor cell lines and in primary tumor tissues from multiple patients. As an added benefit, the activity of the CXCR4 promoter was low in human liver as described previously. Based on these data, the CRAd-CXCR4.F5/3 is a promising novel CRAd agent for SCCHN targeting with low host toxicity.

Original languageEnglish
Pages (from-to)1213-1222
Number of pages10
JournalInternational journal of oncology
Volume31
Issue number5
StatePublished - 1 Nov 2007

Fingerprint

Adenoviridae
Neoplasms
Carcinoma, squamous cell of head and neck
Life Cycle Stages
Tumor Cell Line
Viruses
Liver
Infection
Genes
Proteins

Keywords

  • Adenoviral vector
  • CXCR4 gene
  • Transcriptional targeting
  • Tumor-specific promoter

Cite this

Zhu, Zeng B. ; Mathis, James Michael ; Makhija, Sharmila K. ; Lu, Baogen ; Wang, Minghui ; Ji, Shaonin ; Rivera, Angel A. ; Rosenthal, Eben L. ; Siegal, Gene P. ; Curiel, David T. / Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck. In: International journal of oncology. 2007 ; Vol. 31, No. 5. pp. 1213-1222.
@article{e7ab633f2a824784b98088eb3d125007,
title = "Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck",
abstract = "Conventional cancer treatments are not adequate for the majority of most patients stricken with squamous cell carcinomas of the head and neck (SCCHN). Conditionally replicating adenoviruses (CRAds) represent a promising new modality for treating of neoplastic diseases, including SCCHN. Specifically, CRAd agents infect tumor cells and selectively replicate within them, thus causing their death while sparing surrounding normal cells in the host. Oncolysis results from the replicative life cycle of the virus, which lyses infected tumor cells and releases viral progeny for propagation of infection and resultant lysis of neighboring cancer cells, sparing normal host cells. However, to date there have been two main limitations to successful clinical application of these CRAd agents: poor infectivity and poor tumor specificity. Here we report the construction of a CRAd agent, CRAd-CXCR4.F5/3, in which the adenovirus E1 gene is driven by a tumor-specific CXCR4 promoter, and the viral infectivity is enhanced by a fiber modification, F5/3, containing an Ad3 knob chimeric fiber protein. As expected, this agent improved both of the viral infectivity and tumor specificity as evaluated in established SCCHN tumor cell lines and in primary tumor tissues from multiple patients. As an added benefit, the activity of the CXCR4 promoter was low in human liver as described previously. Based on these data, the CRAd-CXCR4.F5/3 is a promising novel CRAd agent for SCCHN targeting with low host toxicity.",
keywords = "Adenoviral vector, CXCR4 gene, Transcriptional targeting, Tumor-specific promoter",
author = "Zhu, {Zeng B.} and Mathis, {James Michael} and Makhija, {Sharmila K.} and Baogen Lu and Minghui Wang and Shaonin Ji and Rivera, {Angel A.} and Rosenthal, {Eben L.} and Siegal, {Gene P.} and Curiel, {David T.}",
year = "2007",
month = "11",
day = "1",
language = "English",
volume = "31",
pages = "1213--1222",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

Zhu, ZB, Mathis, JM, Makhija, SK, Lu, B, Wang, M, Ji, S, Rivera, AA, Rosenthal, EL, Siegal, GP & Curiel, DT 2007, 'Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck', International journal of oncology, vol. 31, no. 5, pp. 1213-1222.

Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck. / Zhu, Zeng B.; Mathis, James Michael; Makhija, Sharmila K.; Lu, Baogen; Wang, Minghui; Ji, Shaonin; Rivera, Angel A.; Rosenthal, Eben L.; Siegal, Gene P.; Curiel, David T.

In: International journal of oncology, Vol. 31, No. 5, 01.11.2007, p. 1213-1222.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck

AU - Zhu, Zeng B.

AU - Mathis, James Michael

AU - Makhija, Sharmila K.

AU - Lu, Baogen

AU - Wang, Minghui

AU - Ji, Shaonin

AU - Rivera, Angel A.

AU - Rosenthal, Eben L.

AU - Siegal, Gene P.

AU - Curiel, David T.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Conventional cancer treatments are not adequate for the majority of most patients stricken with squamous cell carcinomas of the head and neck (SCCHN). Conditionally replicating adenoviruses (CRAds) represent a promising new modality for treating of neoplastic diseases, including SCCHN. Specifically, CRAd agents infect tumor cells and selectively replicate within them, thus causing their death while sparing surrounding normal cells in the host. Oncolysis results from the replicative life cycle of the virus, which lyses infected tumor cells and releases viral progeny for propagation of infection and resultant lysis of neighboring cancer cells, sparing normal host cells. However, to date there have been two main limitations to successful clinical application of these CRAd agents: poor infectivity and poor tumor specificity. Here we report the construction of a CRAd agent, CRAd-CXCR4.F5/3, in which the adenovirus E1 gene is driven by a tumor-specific CXCR4 promoter, and the viral infectivity is enhanced by a fiber modification, F5/3, containing an Ad3 knob chimeric fiber protein. As expected, this agent improved both of the viral infectivity and tumor specificity as evaluated in established SCCHN tumor cell lines and in primary tumor tissues from multiple patients. As an added benefit, the activity of the CXCR4 promoter was low in human liver as described previously. Based on these data, the CRAd-CXCR4.F5/3 is a promising novel CRAd agent for SCCHN targeting with low host toxicity.

AB - Conventional cancer treatments are not adequate for the majority of most patients stricken with squamous cell carcinomas of the head and neck (SCCHN). Conditionally replicating adenoviruses (CRAds) represent a promising new modality for treating of neoplastic diseases, including SCCHN. Specifically, CRAd agents infect tumor cells and selectively replicate within them, thus causing their death while sparing surrounding normal cells in the host. Oncolysis results from the replicative life cycle of the virus, which lyses infected tumor cells and releases viral progeny for propagation of infection and resultant lysis of neighboring cancer cells, sparing normal host cells. However, to date there have been two main limitations to successful clinical application of these CRAd agents: poor infectivity and poor tumor specificity. Here we report the construction of a CRAd agent, CRAd-CXCR4.F5/3, in which the adenovirus E1 gene is driven by a tumor-specific CXCR4 promoter, and the viral infectivity is enhanced by a fiber modification, F5/3, containing an Ad3 knob chimeric fiber protein. As expected, this agent improved both of the viral infectivity and tumor specificity as evaluated in established SCCHN tumor cell lines and in primary tumor tissues from multiple patients. As an added benefit, the activity of the CXCR4 promoter was low in human liver as described previously. Based on these data, the CRAd-CXCR4.F5/3 is a promising novel CRAd agent for SCCHN targeting with low host toxicity.

KW - Adenoviral vector

KW - CXCR4 gene

KW - Transcriptional targeting

KW - Tumor-specific promoter

UR - http://www.scopus.com/inward/record.url?scp=38449122062&partnerID=8YFLogxK

M3 - Article

C2 - 17912450

AN - SCOPUS:38449122062

VL - 31

SP - 1213

EP - 1222

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -